Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross‐National Comparison Between the US and Taiwan

The hepatitis B virus (HBV) testing rates and patterns in rheumatoid arthritis (RA) patients starting disease‐modifying antirheumatic drugs (DMARDs) have not been well studied. We describe and compare the practice patterns of HBV testing among RA patients in the US and Taiwan.

[1]  W. Alexander,et al.  European Association for the Study of the Liver , 1968 .

[2]  A. Tincani,et al.  Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection , 2016, Arthritis care & research.

[3]  L. Calabrese,et al.  The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al , 2016, Arthritis care & research.

[4]  H. Chuang,et al.  Compliance with risk management plan recommendations on laboratory monitoring of antitumor necrosis factor-α therapy in clinical practice. , 2016, Journal of the Formosan Medical Association = Taiwan yi zhi.

[5]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[6]  J. Singh,et al.  Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study , 2015, Arthritis Research & Therapy.

[7]  Kelvin K. W. Chan,et al.  Poor Recognition of Risk Factors for Hepatitis B by Physicians Prescribing Immunosuppressive Therapy: A Call for Universal Rather than Risk-Based Screening , 2015, PloS one.

[8]  Meng Chen,et al.  Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with Hepatitis B virus carriage and safety observation , 2015, Pakistan journal of medical sciences.

[9]  Y. Falck‐Ytter,et al.  American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .

[10]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[11]  S. Boccia,et al.  HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis , 2014, International journal of rheumatology.

[12]  G. Cunnane,et al.  The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis , 2014, Clinical Rheumatology.

[13]  O. Shibolet,et al.  Immunosuppression and HBV Reactivation , 2013, Seminars in Liver Disease.

[14]  D. Furst,et al.  Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B , 2012, Arthritis care & research.

[15]  J. Ward,et al.  Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable , 2012, Annals of Internal Medicine.

[16]  Jeffrey R Curtis,et al.  2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.

[17]  Jingguo Zhou,et al.  Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs , 2012, Clinical Rheumatology.

[18]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[19]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[20]  L. López-Rosés,et al.  Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy: Analysis of 257 Cases , 2011, Medicine.

[21]  Sebastian Schneeweiss,et al.  A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.

[22]  Jeffrey N Katz,et al.  Validation of rheumatoid arthritis diagnoses in health care utilization data , 2011, Arthritis research & therapy.

[23]  K. Kowatari,et al.  Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients , 2011, Modern rheumatology.

[24]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.

[25]  S. Schneeweiss,et al.  Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis , 2010, Arthritis research & therapy.

[26]  J. Stine,et al.  Rheumatologists' awareness of and screening practices for Hepatitis B virus infection prior to initiating immunomodulatory therapy , 2010, Arthritis care & research.

[27]  A. Craxì,et al.  Implication of normal liver enzymes in liver disease , 2009, Journal of viral hepatitis.

[28]  J. Ward,et al.  Recommendations for identification and public health management of persons with chronic hepatitis B virus infection , 2009, Hepatology.

[29]  Lyn Finelli,et al.  Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. , 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[30]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[31]  G. Minuk,et al.  Chronic hepatitis B infection in Canada. , 2001, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[32]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.